Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (301)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04222309 | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) | suspended | Phase 1 | 10 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05271240 | Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | recruiting | Phase 3 | 432 | Northwell HealthOTHER | 1 | Jun 1, 2026 |
| NCT05954858 | Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma | recruiting | N/A | 32 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05979064 | Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) | recruiting | N/A | 10 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07616986 | LITT for Ultra-early GBM Recurrence | recruiting | N/A | 12 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05116137 | The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors(RESIST) | enrolling by invitation | N/A | 24 | Nova Scotia Health AuthorityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 6 | May 29, 2026 | clinicaltrials |
| NCT06831526 | Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma | recruiting | Early Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04752280 | Glioblastoma Radiotherapy Using IMRT or Proton Beams(GRIPS) | recruiting | N/A | 326 | University Hospital HeidelbergOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07605364 | Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer | not yet recruiting | Phase 2 / Phase 3 | 422 | Alliance for Clinical Trials in OncologyOTHER | 0 | May 26, 2026 | clinicaltrials |
| NCT03688178 | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab(DERIVe) | active not recruiting | Phase 2 | 43 | Annick Desjardins, MDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05736406 | A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 12 | Hemerion TherapeuticsINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT07411690 | Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors(CSF-IMR) | recruiting | — | 200 | Medical University of WarsawOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07604285 | A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma(NOVA-GBM) | not yet recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07413796 | Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures(NEURO-SUTURE) | recruiting | N/A | 382 | Medical University of WarsawOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05500612 | MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy(MANGO) | recruiting | — | 20 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07590726 | PIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors(PIRe) | not yet recruiting | N/A | 160 | Rigshospitalet, DenmarkOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07589257 | A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma | recruiting | Phase 2 | 10 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT00906893 | Evaluation of [18F]-FMISO for Non Operated Glioblastoma(MISOGLIO) | completed | Phase 2 | 14 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04003649 | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | active not recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04477200 | Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma | active not recruiting | Phase 1 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04614909 | Study of Pamiparib in Newly Diagnosed and rGBM | completed | Early Phase 1 | 50 | Nader SanaiOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05281731 | Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma | recruiting | N/A | 40 | Washington University School of MedicineOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05773326 | Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG | terminated | Early Phase 1 | 5 | Nader SanaiOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07042620 | A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery | active not recruiting | N/A | 15 | SonoClear ASINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT02192359 | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03382977 | Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | terminated | Phase 1 / Phase 2 | 70 | VBI Vaccines Inc.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06136611 | Preoperative Preradiotherapy TTFields(PORTRAIT) | recruiting | N/A | 42 | The Christie NHS Foundation TrustOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06964737 | Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas | recruiting | Phase 1 | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04015700 | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | active not recruiting | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma | withdrawn | Phase 2 / Phase 3 | 0 | NRG OncologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT06796335 | Development and Implementation of an Intervention Enhancing Involvement of Relatives to Patients With Acquired Brain Injury or Malignant Brain Tumour | completed | — | 35 | Rigshospitalet, DenmarkOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07284069 | Senicapoc and Perampanel for Newly Diagnosed Glioblastoma(SENIPERA) | recruiting | Early Phase 1 | 36 | Aarhus University HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02331498 | Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme(PAZOGLIO) | active not recruiting | Phase 1 / Phase 2 | 51 | Centre Antoine LacassagneOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04699773 | LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138) | recruiting | N/A | 32 | University of Maryland, BaltimoreOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05557292 | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | terminated | Phase 1 | 7 | Nicholas ButowskiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07343986 | Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma(BATs FUS) | recruiting | Phase 1 | 12 | University of VirginiaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05091866 | Natural Progesterone for the Treatment of Recurrent Glioblastoma | terminated | Early Phase 1 | 4 | Emory UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05629702 | ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids(ARISTOCRAT) | recruiting | Phase 2 | 120 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06649851 | G-CSF After Chemo-radiation in Patients With Glioblastoma | recruiting | Phase 2 | 60 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03491683 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | active not recruiting | Phase 1 / Phase 2 | 52 | Inovio PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT04968366 | Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery | completed | Phase 1 | 11 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05241392 | Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma | active not recruiting | Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05743595 | Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | active not recruiting | Phase 1 | 27 | Washington University School of MedicineOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06176066 | PH Sensitive MRI Based Resections of Glioblastoma | recruiting | Phase 1 | 18 | University of California, Los AngelesOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07560865 | First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma | recruiting | Phase 1 | 9 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562971 | Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)(FIDES) | not yet recruiting | Phase 1 / Phase 2 | 20 | UMC UtrechtOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07365124 | MRinRT: Swansea University and SWWCC Collaboration Study.(MRinRT) | not yet recruiting | — | 165 | Swansea Bay University Health BoardOTHER | 1 | Apr 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 1, 2026source: clinicaltrials